Nitec Pharma AG, a Swiss specialty pharmaceutical company, said it has obtained a CHF 24 million (€15.2 million) equity investment from five institutions to finance preparations for the approval and launch of Lodotra, its treatment for rheumatoid arthritis and other inflammatory diseases as well as the development of a product for pain.
